PNN DigitalPNN Digital
    Facebook Twitter Instagram
    Wednesday, July 30
    Trending
    • Stronger Together: India and UAE Seal Strategic Defence Boost at 13th JDCC Meet
    • Mukkti Foundation and Smita Thackeray Launch Free Kala & Natya Workshop for Underprivileged Children
    • Eco Recycling Reports Rs 8 Cr PAT, up 268 Percent in Consolidated Q1 FY26
    • Avani Institute of Design Launches Innovative Five-Year Integrated B.Des + M.Des Dual Degree Program
    • Aayush Wellness Announces 2nd Interim Dividend
    • How Vivanta Stays Is Quietly Shaking Up India’s Luxury Villa Market With Heart and Hustle
    • Dragon Tattoos Gallery, A Leading Tattoo Studio in Ahmedabad
    • DPIIT Partners with TICE to Boost Startup Visibility and Media Outreach Across India
    Submit News
    PNN DigitalPNN Digital
    Subscribe
    • Home
    • News
    • Business
    • Entertainment
    • National
    • Lifestyle
    • More
      • Sports
      • Health
      • Finance
      • Education
    PNN DigitalPNN Digital
    Home»Business

    Syncom Formulations (India) Limited Reported Its Excellent Performance For 4th Quarter

    Syncom Formulations (India) Ltd posts strong Q4 and full-year FY2025 results with major gains in exports and PAT.
    PNN NewsdeskPNN Newsdesk Business 2 Mins Read
    Syncom Formulations - PNN
    Profit After Tax Up by 139 % (4th Quarter FY 2024-25 Consolidated Results)
    Share
    Facebook Twitter LinkedIn Pinterest Email

    Mumbai (Maharashtra) [India], June 2: Syncom Formulation ( India ) Ltd , a Speciality Pharmaceutical Formulation company Today reported its excellent performance for 4th quarter and year ended 31st March 25. 

    Q4 FY2025 Performance highlights (compared to Q4 FY2024): 

    • Revenue from operations at Rs.14888 Lacs against Rs.7457 Lacs.; up 100%. 
    • EBITDA at Rs.2469 Lacs against Rs.1252 Lacs; Up 97%; 
    • Profit after tax at Rs.1769 Lacs against Rs.740 Lacs.; Up 139%;

    FY 2025 Performance highlights (compared to FY2024): 

    • Revenue from operations at Rs.46501 Lacs against Rs.26339 Lacs; Up76%. 
    • EBITDA at Rs.7157 Lacs. againstRs.4317 Lacs.; Up 66%; 
    • Profit after taxatRs.4943 Lacs. againstRs.2531 Lacs.; Up 95%;

    Segment-wise Performance

    Markets FY 24-25 ( Rs in Lacs) FY 23-24 ( Rs In Lacs )   Growth %
    Export 40003 21216 88%
    Domestic 5734 4708 22%

    About  Syncom Formulations (India) Limited 

    Established in 1988, Syncom Formulations (India) Limited has grown into a leading name in the Indian pharmaceutical sector. The company has consistently posted profits since inception and is renowned for delivering high-quality pharmaceutical formulations across diverse therapeutic segments. 

    “We are proud of our performance this year, which reflects the success of our strategic initiatives, operational efficiency, and strong demand in both domestic and international markets. We remain committed to expanding our global presence and delivering sustained value to all stakeholders.” 

    Global Presence 

    Syncom has built a strong international footprint, operating in nearly 25 countries with a portfolio of over 400 registered products. The company’s focus on quality, affordability, timely delivery, and excellent customer service has cemented enduring relationships with clients globally and ensured consistent performance. 

    Domestic Initiatives and Growth Strategy 

    In India, Syncom operates through multiple focused divisions, each addressing specific healthcare segments. With a strong field force of around 1,000 Medical Representatives (MRs) strategically placed across the country, the company is well-positioned for accelerated growth. 

    These MRs will be pivotal in expanding market coverage, deepening doctor engagement, and driving the company’s presence in untapped territories. Combined with robust marketing initiatives, Syncom’s strategy will reinforce its position as a key player in the domestic pharmaceutical market.

    If you object to the content of this press release, please notify us at [email protected]. We will respond and rectify the situation within 24 hours.

    export growth Financial Performance pharma results q4 fy25 results syncom formulations
    PNN Newsdesk

    Keep Reading

    Mukkti Foundation and Smita Thackeray Launch Free Kala & Natya Workshop for Underprivileged Children

    Eco Recycling Reports Rs 8 Cr PAT, up 268 Percent in Consolidated Q1 FY26

    Avani Institute of Design Launches Innovative Five-Year Integrated B.Des + M.Des Dual Degree Program

    Aayush Wellness Announces 2nd Interim Dividend

    How Vivanta Stays Is Quietly Shaking Up India’s Luxury Villa Market With Heart and Hustle

    Dragon Tattoos Gallery, A Leading Tattoo Studio in Ahmedabad

    Recent Posts
    • Stronger Together: India and UAE Seal Strategic Defence Boost at 13th JDCC Meet
    • Mukkti Foundation and Smita Thackeray Launch Free Kala & Natya Workshop for Underprivileged Children
    • Eco Recycling Reports Rs 8 Cr PAT, up 268 Percent in Consolidated Q1 FY26
    • Avani Institute of Design Launches Innovative Five-Year Integrated B.Des + M.Des Dual Degree Program
    • Aayush Wellness Announces 2nd Interim Dividend

    Stronger Together: India and UAE Seal Strategic Defence Boost at 13th JDCC Meet

    30/07/2025

    Mukkti Foundation and Smita Thackeray Launch Free Kala & Natya Workshop for Underprivileged Children

    30/07/2025

    Eco Recycling Reports Rs 8 Cr PAT, up 268 Percent in Consolidated Q1 FY26

    30/07/2025

    Avani Institute of Design Launches Innovative Five-Year Integrated B.Des + M.Des Dual Degree Program

    30/07/2025

    Aayush Wellness Announces 2nd Interim Dividend

    30/07/2025

    How Vivanta Stays Is Quietly Shaking Up India’s Luxury Villa Market With Heart and Hustle

    30/07/2025
    Facebook Instagram Twitter
    • Legal Disclaimer
    • Privacy Policy
    • Contact Us
    • About Us
    © 2025 PNN Digital. Designed by Primex Media Services.

    Type above and press Enter to search. Press Esc to cancel.